Overview
Osteochondrodysplastic nanism-deafness-retinitis pigmentosa syndrome is an extremely rare condition that has been described in medical literature under this historical name, though it is now considered an obsolete classification. The condition combines several features: a form of short stature caused by abnormal bone and cartilage development (osteochondrodysplasia or skeletal dysplasia), hearing loss (deafness), and a progressive eye condition called retinitis pigmentosa that causes gradual vision loss. Patients with this syndrome typically present with disproportionate short stature due to problems with how bones grow and develop, along with sensorineural hearing impairment and night blindness or tunnel vision that worsens over time. Because this diagnosis is now considered obsolete, it is possible that cases previously described under this name have been reclassified into other more precisely defined syndromes, potentially including conditions in the spectrum of skeletal ciliopathies or related multi-system disorders. The treatment landscape is largely supportive, focusing on managing each individual symptom — orthopedic care for skeletal problems, hearing aids or cochlear implants for deafness, and low-vision aids for retinitis pigmentosa. There is no known cure. Patients benefit from coordinated care involving multiple specialists.
Also known as:
Key symptoms:
Short stature (dwarfism)Abnormal bone and cartilage developmentHearing loss or deafnessNight blindnessTunnel vision or progressive vision lossShort limbs relative to the trunkJoint stiffness or limited joint movementDifficulty seeing in dim lightDelayed growth in childhoodPossible spinal abnormalities
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for OBSOLETE: Osteochondrodysplatic nanism-deafness-retinitis pigmentosa syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for OBSOLETE: Osteochondrodysplatic nanism-deafness-retinitis pigmentosa syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for OBSOLETE: Osteochondrodysplatic nanism-deafness-retinitis pigmentosa syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to OBSOLETE: Osteochondrodysplatic nanism-deafness-retinitis pigmentosa syndrome.
Community
No community posts yet. Be the first to share your experience with OBSOLETE: Osteochondrodysplatic nanism-deafness-retinitis pigmentosa syndrome.
Start the conversation →Latest news about OBSOLETE: Osteochondrodysplatic nanism-deafness-retinitis pigmentosa syndrome
No recent news articles for OBSOLETE: Osteochondrodysplatic nanism-deafness-retinitis pigmentosa syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Has genetic testing been done to identify the specific cause of this condition, and could it be reclassified under a more current diagnosis?,How quickly is the vision loss expected to progress, and are there any treatments that might slow it down?,What type of hearing device would be most helpful, and how often should hearing be retested?,Are there any clinical trials or emerging therapies that might be relevant?,What orthopedic monitoring or interventions are recommended for the skeletal issues?,What educational or workplace accommodations should we request?,Should other family members be tested for carrier status?
Common questions about OBSOLETE: Osteochondrodysplatic nanism-deafness-retinitis pigmentosa syndrome
What is OBSOLETE: Osteochondrodysplatic nanism-deafness-retinitis pigmentosa syndrome?
Osteochondrodysplastic nanism-deafness-retinitis pigmentosa syndrome is an extremely rare condition that has been described in medical literature under this historical name, though it is now considered an obsolete classification. The condition combines several features: a form of short stature caused by abnormal bone and cartilage development (osteochondrodysplasia or skeletal dysplasia), hearing loss (deafness), and a progressive eye condition called retinitis pigmentosa that causes gradual vision loss. Patients with this syndrome typically present with disproportionate short stature due to p
How is OBSOLETE: Osteochondrodysplatic nanism-deafness-retinitis pigmentosa syndrome inherited?
OBSOLETE: Osteochondrodysplatic nanism-deafness-retinitis pigmentosa syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does OBSOLETE: Osteochondrodysplatic nanism-deafness-retinitis pigmentosa syndrome typically begin?
Typical onset of OBSOLETE: Osteochondrodysplatic nanism-deafness-retinitis pigmentosa syndrome is childhood. Age of onset can vary across affected individuals.